David Eric Ouedraogo, Alain Makinson, Nils Kuster, Nicolas Nagot, Pierre-Alain Rubbo, Karine Bollore, Vincent Foulongne, Guillaume Cartron, Daniel Olive, Jacques Reynes, Jean-Pierre Vendrell and Edouard Tuaillon
Accepted Abstracts: J Cancer Sci Ther
Background: Despite the use of combined antiretroviral therapy, HIV-infected individuals have a higher risk of developing B-cell lymphoma compared to the general population. We aim to explore whether lymphocyte activation, increase in Th1 response as well as markers of EBV reactivation, may precede lymphoma diagnosis. Methods: Thirteen cases and 26 controls matched on CD4+ T-cell count and HIV plasma viral load were identified. Samples were collected 0 to 5 years prior to B-cell lymphoma diagnosis. Seven out of thirteen (54%) and 16/26 (61.5%) of cases and controls were receiving antiretroviral therapy at the time of sampling, respectively. CD8+ T-cell activation and Th1 cytokine concentrations were measured before lymphoma onset, together with IgG antibodies directed against viral capsid antigen (VCA) and serum levels of EBV DNA. Results: A higher level of CD8+ T-cell activation was observed in patients developing lymphoma. Four out of seven Th1 cytokine serum concentrations were significantly higher in patients with lymphoma than in the control group: IL-2R, IL-12 p40/70, IFN-g-inducible protein 10 (IP-10) and monokine induced by IFN-g (MIG). Anti-VCA IgG level were significantly higher in cases than in controls. Four cases (30%) but no controls had detectable EBV DNA in serum. Conclusion: A higher level of T-cell activation, Th1 cytokine serum concentration and markers of EBV replication, preceded B-cell lymphoma diagnosis. This may suggest that viral antigen stimulation is associated with the genesis of lymphoma in HIVinfected patients.
Cancer Science & Therapy received 3968 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 